الفهرس 
A Pharmaceutical Study on Nanotechnology in Developing Formulation of Novel Drug Delivery Systems
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
Hepatitis C virus (HCV) is a significant public health concern that threatens millions of individuals worldwide. Daclatasvir (DAC) is a recently promising direct-acting antiviral approved for treating HCV infection around the world. The goal of this thesis is to enhance DAC delivery to the liver and increase its residence time. This goal was achieved by adopting two approaches of drug targeting. The first approach was passive targeting through encapsulating DAC into novel polyethylene glycol (PEG) decorated bilosomes (PEG-BILS) to achieve enhanced drug delivery to the liver.The second approach is active targeting by tailoring mannosylated liposomes targeting Mannose receptors on non-parenchymal cells of the liver. Chapter 1: Formulation and Evaluation of Daclatasvir ultra-deformable bilosomes with modified surface with polyethylene glycol. In this chapterPassive targeting strategy was adopted where, DAC was encapsulated into novel polyethylene glycol decorated bilosomes to achieve enhanced drug delivery to the liver. DAC-loaded BILS was primed by thin film hydrating technique. The study of the impact of various formulation variables on BILS properties and picking up the optimal formulation was generated using Design-Expert® software. The optimum preparation was then pegylated via incorporation of PEG-6-stearate (5% w/w, respecting to the lipid phase). The optimum PEG-BILS formulation (containing PL: SDC ratio (5:1), 5 mg Cholesterol, 30 min sonication yielded spherical vesicles in the nanoscale (200 ± 15.2 nm), elevated percent of entrapment efficiency (95.5 ±7.77%), and a sustained release profile of DAC with 35.11 ± 2.3% release.